  See all
 |
Articles: Chemotherapy/Oncology |
Prior Articles
Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09
Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors
Clinical Cancer Research, 12/01/09 Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology, 12/01/09 Seliciclib in malignancies
Expert Opinion on Investigational Drugs, 11/30/09 Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly - A Mini-Review
Gerontology, 11/30/09
Free full text
Revew Article
Valproic acid restores ERalpha and antiestrogen sensitivity to ERalpha-negative breast cancer cells
Molecular and Cellular Endocrinology, 11/25/09
Free full text
Exclusive Author Commentary N2 Disease in Patients With Head and Neck Squamous Cell Cancer Treated With Chemoradiotherapy
Archives of Otolaryngology, 11/25/09 Salvage treatment with upfront melphalan 100 mg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma
Annals of Hematology, 11/24/09 Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Journal of Clinical Oncology, 11/24/09 The rationale for mTOR inhibition in epithelial ovarian cancer
Expert Opinion on Investigational Drugs, 11/24/09 Ascorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity Against Acute Promyelocytic Leukemia
Archives of Drug Information, 11/24/09
Exclusive Author Commentary Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study
Annals of Hematology, 11/24/09 Good clinical endpoints with denosumab in osteoporosis and cancer
Expert Opinion in Pharmacotherapy, 11/23/09 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience
Journal of Clinical Oncology, 11/23/09 VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: A multicenter experience
Archives of Gerontology and Geriatrics, 11/23/09 Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma
British Journal of Haematology, 11/20/09 Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
British Journal of Cancer, 11/20/09 Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology, 11/20/09 A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma
British Journal of Cancer, 11/20/09 Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
Clinical Cancer Research, 11/20/09
|
|
Receive free subspecialty "5-minute updates" via email
|
|
Indexed Journals: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacist
more...
|
250 Available Pages
|
|
